| Benign prostatic hyperplasia. | |
| | |
MedLine Citation:
|
PMID: 20497842 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This article reviews the epidemiology of benign prostatic hyperplasia (BPH), evaluation of patients with lower urinary tract symptomatology (LUTS), and management of patients with BPH and LUTS. The evaluation includes history and physical examination, laboratory testing, and specialized studies. The management includes medical and surgical options. Medical options include alpha-1-adrenergic receptor blockers, 5alpha-reductase inhibitors, and combinations of these and other medications. Surgical options include endoscopic procedures, open procedures, and laser procedures. |
| | |
Authors:
|
David R Paolone |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Clinics in geriatric medicine Volume: 26 ISSN: 1557-8623 ISO Abbreviation: Clin. Geriatr. Med. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-25 Completed Date: 2010-09-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8603766 Medline TA: Clin Geriatr Med Country: United States |
Other Details:
|
Languages: eng Pagination: 223-39 Citation Subset: IM |
Copyright Information:
|
Copyright 2010. Published by Elsevier Inc. |
Affiliation:
|
Department of Urology, University of Wisconsin School of Medicine and Public Health, UW Health Urology, 1 South Park Street, Madison, WI 53715, USA. david.paolone@uwmf.wisc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Combined Modality Therapy Drug Therapy, Combination Evidence-Based Medicine Humans Laser Therapy Male Middle Aged Prostatectomy Prostatic Hyperplasia / complications, diagnosis*, epidemiology, therapy* Treatment Outcome Urination Disorders / complications, therapy |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Late-life onset hypogonadism: a review.
Next Document: Prostate Cancer in the Older Man: Conflict Between Tumor Biology and Medical Advancement.